GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camp4 Therapeutics Corp (NAS:CAMP) » Definitions » Insider Ownership

CAMP (Camp4 Therapeutics) Insider Ownership : 3.60 % (As of Mar. 30, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Camp4 Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Camp4 Therapeutics's insider ownership is 3.60%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Camp4 Therapeutics's Institutional Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Camp4 Therapeutics's Float Percentage Of Total Shares Outstanding is 77.97%.


Camp4 Therapeutics Insider Ownership Historical Data

The historical data trend for Camp4 Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camp4 Therapeutics Insider Ownership Chart

Camp4 Therapeutics Historical Data

The historical data trend for Camp4 Therapeutics can be seen below:

2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28
Insider Ownership 3.72 3.60 3.60 3.60 3.60

Camp4 Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Camp4 Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA, USA
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.